Back to Results
First PageMeta Content
Glycosaminoglycans / Oral and maxillofacial surgery / Oral surgery / Restylane / Hyaluronan / Lip enhancement / Adverse event / Food and Drug Administration / Medical device / Medicine / Clinical research / Pharmaceutical industry


Microsoft Word - Executive Summary-FDA-Final.doc
Add to Reading List

Open Document

File Size: 208,12 KB

Share Result on Facebook

City

Study / Protocol / Scottsdale / /

Company

Medicis Aesthetics Inc. / Applicant/Manufacturer Information Medicis Aesthetics Inc. / Executive Summary Medicis Aesthetics Inc. / /

Currency

pence / /

Event

FDA Phase / /

IndustryTerm

manufacturing information / /

MedicalTreatment

Restylane / Plastic and Reconstructive Surgery / /

Organization

FDA / Division of Surgical / Orthopedic / and Restorative Devices / Food and Drug Administration / Center for Devices and Radiological Health / /

Position

General / Treating Investigator / Blinded Evaluator / Executive / /

Product

P040024 / MA-1300-15 / /

ProvinceOrState

Arizona / /

PublishedMedium

the FDA review / /

Technology

research protocols / /

SocialTag